Critical Review: Eloxx Pharmaceuticals (ELOX) and Its Rivals

Eloxx Pharmaceuticals (NASDAQ:ELOX) is one of 902 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Eloxx Pharmaceuticals to related businesses based on the strength of its earnings, valuation, institutional ownership, dividends, profitability, risk and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Eloxx Pharmaceuticals and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	2	2	3.00
Eloxx Pharmaceuticals Competitors	7616	13668	25502	1003	2.42

Eloxx Pharmaceuticals presently has a consensus price target of $38.33, suggesting a potential upside of 139.58%. As a group, “Pharmaceuticals” companies have a potential upside of 28.13%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Eloxx Pharmaceuticals is more favorable than its rivals.

Profitability

This table compares Eloxx Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Eloxx Pharmaceuticals Competitors	-2,319.23%	-223.52%	-16.98%

Volatility and Risk

Eloxx Pharmaceuticals has a beta of -1862.26, meaning that its share price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ rivals have a beta of -3.17, meaning that their average share price is 417% less volatile than the S&P 500.

Valuation & Earnings

This table compares Eloxx Pharmaceuticals and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	-$5.99 million	-10.39
Eloxx Pharmaceuticals Competitors	$3.55 billion	$3.14 billion	547.53

Eloxx Pharmaceuticals’ rivals have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Eloxx Pharmaceuticals beats its rivals on 7 of the 13 factors compared.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.